Market Insight – Merck & Co/Schering-Plough cuts a finer figure
This article was originally published in Scrip
Executive Summary
Merck & Co has chosen a formidable merger partner in Schering-Plough in a deal that promises an increased focus on neurology and infectious diseases, a shift towards specialist care in cardiovascular diseases as well as an impressive late-stage pipeline, writes Dr Nick Karachalias